Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

뉴스 본문을 불러오고 있어요.

Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis | 웨이프 WAPE

Reported Sunday, Amgen's Repatha Cuts First Major Cardiovascular Event Risk By 29% In High-Risk Diabetes Patients In VESALIUS-CV Subgroup Analysis

기사 요약

관련 종목

댓글 —